

AMENDMENTS TO THE CLAIMS:

This listing will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1 (currently amended): ~~Use of A method for stimulating~~ peripheral-blood mononuclear cells ~~that have been stimulated~~ via cascade priming (CAPRI cells), ~~which are obtainable by~~ comprising the following stimulation process:

- peripheral-blood mononuclear cells (PBMC) are subjected to primary stimulation by means of CD3 antibodies or by means of immobilised CD3 antibodies,
- naïve PMBC are added to the PBMC that have been subjected to primary stimulation and are incubated for the purpose of stimulating the naïve PBMC,

the primary stimulation of the PBMC and/or the stimulation of the naïve PBMC being undertaken in the presence of interleukin-2 and/or interleukin-4 and/or interferon- γ , for the purpose of providing an agent for the treatment of cancerous diseases.

Claim 2 (currently amended): ~~Use~~ The method according to Claim 1, ~~characterised in that use is made of~~ comprising using autologous or allogenic CAPRI cells.

Claim 3 (currently amended): ~~Use~~ The method according to Claim 1 ~~or 2~~, ~~characterised in that~~ wherein the ratio of PBMC subjected to primary stimulation to naïve PBMC is between 1:10 and 10:1.

Claim 4 (currently amended): Use The method according to Claim 3, ~~characterised in that~~ wherein the ratio of PBMC subjected to primary stimulation to naïve PBMC is 1:1.

Claim 5 (currently amended): Use The method according to ~~one of Claims 1-4~~ claim 1, ~~characterised in that~~ wherein the CAPRI cells are administered by means of an injection intradermally, intravenously and/or intramuscularly and/or in or around the tumour.

Claim 6 (currently amended): Use The method according to Claim 5, ~~characterised in that~~ wherein the CAPRI cells are administered by means of an injection intradermally and intravenously.

Claim 7 (currently amended): Use The method according to Claim 5 ~~or 6~~, ~~characterised in that~~ wherein the CAPRI cells are administered in a dosage of 0.5-30 million cells per injection.

Claim 8 (currently amended): Use The method according to Claim 7, ~~characterised in that~~ wherein the CAPRI cells are administered in a dosage of 1-20 million cells per injection.

Claim 9 (currently amended): Use The method according to ~~one of Claims 1-6~~ claim 1, ~~characterised in that~~ wherein the CAPRI cells are administered together with CD3-stimulated lymphocytes.

Claim 10 (currently amended): Use The method according to Claim 9, ~~characterised in that~~ wherein the CD3-stimulated lymphocytes are administered in a dosage of 1-20 million cells per injection.

Claim 11 (currently amended): Use The method according to Claim 9 ~~or 10~~, ~~characterised in that~~ wherein the CD3-stimulated lymphocytes are administered by means of an injection intradermally and/or intramuscularly.

Claim 12 (currently amended): Use The method according to ~~one of Claims 9-11~~ claim 9, ~~characterised in that~~ wherein the CD3-stimulated lymphocytes are administered into a different place in the body of the patient than the CAPRI cells.

Claim 13 (currently amended): Use The method according to ~~one of Claims 1-12~~ claim 1, ~~characterised in that it~~ which is undertaken together with a medicinal or radiotherapeutic treatment that is matched to the type of disease.